Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
Abstract Introduction This trial was conducted to compare the efficacy of low dose once‐a‐week cisplatin and once‐every‐3‐weeks cisplatin with radiation in locally advanced head and neck squamous cell carcinoma (LAHNSCC). The current analysis focuses on the quality of life (QoL) of patients in this...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4715 |
| _version_ | 1811243548681437184 |
|---|---|
| author | Nandini S. Menon Vanita Noronha Vijay Maruti Patil Amit Joshi Atanu Bhattacharjee Devanshi Kalra Sarbani Ghosh Laskar Vijayalakshmi Mathrudev Kavita Nawale Arati S. Bhelekar Kumar Prabhash |
| author_facet | Nandini S. Menon Vanita Noronha Vijay Maruti Patil Amit Joshi Atanu Bhattacharjee Devanshi Kalra Sarbani Ghosh Laskar Vijayalakshmi Mathrudev Kavita Nawale Arati S. Bhelekar Kumar Prabhash |
| author_sort | Nandini S. Menon |
| collection | DOAJ |
| description | Abstract Introduction This trial was conducted to compare the efficacy of low dose once‐a‐week cisplatin and once‐every‐3‐weeks cisplatin with radiation in locally advanced head and neck squamous cell carcinoma (LAHNSCC). The current analysis focuses on the quality of life (QoL) of patients in this trial. Methods In this phase III randomized trial, patients with nonmetastatic LAHNSCC were randomized to receive cisplatin 30 mg/m2 once‐a‐week or 100 mg/m2 once every‐ 3‐weeks concurrently with radiotherapy. The primary endpoint was locoregional control. QoL was a key secondary endpoint. QoL was assessed using EORTC QLQ‐C30 and QLQ‐H&N35. QoL data were assessed at baseline, days 22 and 43 during treatment; and at 6, 12, 24 months. The linear mixed‐effects model was used for longitudinal analysis of QoL to determine the impact of treatment (arm) and time on QoL. Results Three hundred patients were enrolled, data of 150 patients with available baseline QoL were analyzed. There was no significant difference in the global health status/QoL of the two treatment arms (p = 0.8664). There was no significant difference in the longitudinal QoL scores between the two treatment arms in all scales except constipation (p = 0.0096), less sexuality (p = 0.0002,), and financial difficulty (p = 0.0219). There was a worsening of the QoL scores in all scales in both arms during treatment, which improved after treatment completion in most scales. Conclusion The use of once‐every‐3‐weeks cisplatin did not adversely impact QoL as compared to once‐a‐week cisplatin in combination with radiotherapy in LAHNSCC. |
| first_indexed | 2024-04-12T14:10:24Z |
| format | Article |
| id | doaj.art-f7c8e79620cf42e8aa6c71b27c061838 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-12T14:10:24Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-f7c8e79620cf42e8aa6c71b27c0618382022-12-22T03:29:56ZengWileyCancer Medicine2045-76342022-11-0111213939394810.1002/cam4.4715Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatinNandini S. Menon0Vanita Noronha1Vijay Maruti Patil2Amit Joshi3Atanu Bhattacharjee4Devanshi Kalra5Sarbani Ghosh Laskar6Vijayalakshmi Mathrudev7Kavita Nawale8Arati S. Bhelekar9Kumar Prabhash10Department of Medical Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaDepartment of Medical Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaDepartment of Medical Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaDepartment of Medical Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaSection of Biostatistics, Centre for Cancer Epidemiology, Advanced Centre for Treatment Research and Education in Cancer Navi Mumbai IndiaDepartment of Medical Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaDepartment of Radiation Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaDepartment of Medical Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaDepartment of Medical Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaDepartment of Medical Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaDepartment of Medical Oncology, Tata Memorial Centre Homi Bhabha National Institute Mumbai IndiaAbstract Introduction This trial was conducted to compare the efficacy of low dose once‐a‐week cisplatin and once‐every‐3‐weeks cisplatin with radiation in locally advanced head and neck squamous cell carcinoma (LAHNSCC). The current analysis focuses on the quality of life (QoL) of patients in this trial. Methods In this phase III randomized trial, patients with nonmetastatic LAHNSCC were randomized to receive cisplatin 30 mg/m2 once‐a‐week or 100 mg/m2 once every‐ 3‐weeks concurrently with radiotherapy. The primary endpoint was locoregional control. QoL was a key secondary endpoint. QoL was assessed using EORTC QLQ‐C30 and QLQ‐H&N35. QoL data were assessed at baseline, days 22 and 43 during treatment; and at 6, 12, 24 months. The linear mixed‐effects model was used for longitudinal analysis of QoL to determine the impact of treatment (arm) and time on QoL. Results Three hundred patients were enrolled, data of 150 patients with available baseline QoL were analyzed. There was no significant difference in the global health status/QoL of the two treatment arms (p = 0.8664). There was no significant difference in the longitudinal QoL scores between the two treatment arms in all scales except constipation (p = 0.0096), less sexuality (p = 0.0002,), and financial difficulty (p = 0.0219). There was a worsening of the QoL scores in all scales in both arms during treatment, which improved after treatment completion in most scales. Conclusion The use of once‐every‐3‐weeks cisplatin did not adversely impact QoL as compared to once‐a‐week cisplatin in combination with radiotherapy in LAHNSCC.https://doi.org/10.1002/cam4.4715chemoradiationcisplatinhead and neck cancerquality of life |
| spellingShingle | Nandini S. Menon Vanita Noronha Vijay Maruti Patil Amit Joshi Atanu Bhattacharjee Devanshi Kalra Sarbani Ghosh Laskar Vijayalakshmi Mathrudev Kavita Nawale Arati S. Bhelekar Kumar Prabhash Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin Cancer Medicine chemoradiation cisplatin head and neck cancer quality of life |
| title | Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin |
| title_full | Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin |
| title_fullStr | Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin |
| title_full_unstemmed | Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin |
| title_short | Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin |
| title_sort | quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once a week versus once every 3 weeks cisplatin |
| topic | chemoradiation cisplatin head and neck cancer quality of life |
| url | https://doi.org/10.1002/cam4.4715 |
| work_keys_str_mv | AT nandinismenon qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT vanitanoronha qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT vijaymarutipatil qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT amitjoshi qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT atanubhattacharjee qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT devanshikalra qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT sarbanighoshlaskar qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT vijayalakshmimathrudev qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT kavitanawale qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT aratisbhelekar qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin AT kumarprabhash qualityoflifeinpatientswithlocallyadvancedheadandnecksquamouscellcarcinomaundergoingconcurrentchemoradiationwithonceaweekversusonceevery3weekscisplatin |